Transthyretin Cardiac Amyloidosis
📧 Sign up to get email alerts when something new happens for Transthyretin Cardiac Amyloidosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-03-16Clinical Trial Update: Multicenter Study for the Validation of an AI-based ECG Platform for Early Cardiac Amyloidosis Diagnosis
A multicenter study is underway to validate an AI-based ECG platform for the early diagnosis of transthyretin cardiac amyloidosis. The trial…
-
CLINICAL_TRIALS research · 2026-01-07Clinical Trial Update: Real-Life Clinical Efficacy of Acoramidis in Participants With ATTR-CM and Association With Cardiac Biomarkers [Phase 4]
This clinical trial update notes a Phase 4 study of Acoramidis in transthyretin cardiac amyloidosis (ATTR-CM) assessing real-world efficacy …
-
CLINICAL_TRIALS research · 2025-09-05Clinical Trial Update: Safety, Efficacy, and Pharmacokinetics of Tafamidis in Patients With Transthyretin-mediated Amyloidosis Post Orthotopic Heart Transplantation [Phase 4]
Phase 4 clinical trial evaluating safety, efficacy, and pharmacokinetics of tafamidis in patients with transthyretin cardiac amyloidosis aft…
-
CLINICAL_TRIALS trial_result · 2025-08-15Clinical Trial Update: Prevalence of wtATTR-CM After Carpal Tunnel Release Surgery [NA]
A completed clinical trial evaluating the prevalence of wild-type transthyretin cardiac amyloidosis after carpal tunnel release surgery.
-
CLINICAL_TRIALS research · 2025-04-02Clinical Trial Update: Description of a Retrospective Cohort of Patients With Transthyretin Cardiac Amyloidosis (ATTR-CA) in Internal Medicine
A clinical trial update describes a retrospective cohort of patients with transthyretin cardiac amyloidosis (ATTR-CM) in internal medicine. …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2024-12-02Clinical Trial Update: Effect of Angiotensin Receptor/Neprilysin Inhibitors on Transthyretin Cardiac Amyloidosis and Heart Failure with Reduced Ejection Fraction [Phase 3]
A Phase 3 study is exploring the effects of an angiotensin receptor/neprilysin inhibitor on transthyretin cardiac amyloidosis (ATTR-CM) and …
-
CLINICAL_TRIALS trial_result · 2024-08-07Clinical Trial Update: Prevalence of Transthyretin Cardiac Amyloidosis in Clinically Significant Aortic Stenosis [EARLY_Phase 1]
An early-phase Phase 1 study evaluated the prevalence of transthyretin cardiac amyloidosis among patients with clinically significant aortic…
-
CLINICAL_TRIALS trial_result · 2024-07-11Clinical Trial Update: A Study of Doxycycline and Tauroursodeoxycholic Acid (Doxy/TUDCA) Plus Standard Supportive Therapy Versus Standard Supportive Therapy Alone in Cardiac Amyloidosis Caused by Transthyretin [Phase 3]
A Phase 3 trial comparing doxycycline plus tauroursodeoxycholic acid (Doxy/TUDCA) with standard supportive therapy versus standard therapy a…
-
CLINICAL_TRIALS research · 2024-04-16Clinical Trial Update: Long-term Monitoring of Patients With Cardiac Amyloidosis With Implantable Event Monitors [NA]
A completed clinical trial assessing long-term monitoring of patients with transthyretin cardiac amyloidosis using implantable event monitor…
-
CLINICAL_TRIALS research · 2023-09-11Clinical Trial Update: Imaging for the Evaluation of Transthyretin Cardiac Amyloidosis Prevalence of Patients Over 65 Hospitalized in Cardiology Wards (the IMPACT Study) [Phase 3]
A Phase 3 clinical trial update examining imaging for evaluating the prevalence of transthyretin cardiac amyloidosis in patients over 65 hos…
-
CLINICAL_TRIALS trial_result · 2023-03-20Clinical Trial Update: Phase 2 Study to Evaluate ALN-TTRSC (Revusiran) in Patients With Transthyretin (TTR) Cardiac Amyloidosis [Phase 2]
Phase 2 study evaluating ALN-TTRSC (Revusiran) in patients with transthyretin cardiac amyloidosis has completed.